Erasca Announces Pricing of Upsized Public Offering of Common Stock

Group 1 - Erasca, Inc. announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at a price of $10.00 per share, expecting gross proceeds of $225.0 million before expenses [1] - The offering is set to close on January 23, 2026, subject to customary closing conditions [1] - Erasca has granted underwriters a 30-day option to purchase up to an additional 3,375,000 shares at the offering price [1] Group 2 - The net proceeds from the offering will be used to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes [2] - J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering [2] Group 3 - The securities are being offered under a shelf registration statement on Form S-3, which was declared effective on August 22, 2025 [3] - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus supplement will also be filed [4] Group 4 - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, aiming to "erase cancer" [6] - The company was co-founded by pioneers in precision oncology and RAS targeting, with a scientific advisory board comprising leading experts in the field [6]